Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Dec 2023
The USA. s. For adult patients who need nirogacestat (Ogsiveo) due to their desmoid tumors progressing, the Food and Drug Administration has approved the tablets.
Read Full News8 Pulmonology Headlines You Missed in Q3 2026
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Here's some of what is coming soon to NeurologyLive® this week.
New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.
Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.
6 Nephrology Headlines You Missed in September 2026
1.
Q&A: Breast cancer facts that could save lives
2.
No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy
3.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
4.
Woman Loses 6-Year Battle With Mouth Tumor
5.
EMA OKs Two Treatments for Small Cell Lung Cancer
1.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
Geriatric Medicine Through Long-Term Functional Survivorship After Cancer in Older Adults
4.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
5.
Spatial Mapping of Tumor Cell States: Integrating Biology, Technology, and Clinical Practice
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
Understanding the Common Causes of Anemia
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Clinical Insights in Hematology
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge